PMID: 9186533Apr 1, 1997Paper

Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia

European Journal of Haematology
Anders WahlinMichael Hedenus

Abstract

The results of an intensive treatment program for patients 16-60 yr of age with de novo acute myeloid leukemia are presented. The patients were given conventional induction treatment with daunorubicin and cytarabine. Patients not entering complete remission (CR) after 1 course of daunorubicin/cytarabine were given 1 course of amsacrine/etoposide/cytarabine. Those entering complete remission received 3 consolidation courses using mitoxantrone, etoposide, amsacrine and cytarabine. One hundred and eighteen patients were enrolled. Complete remission was attained after 1-2 courses in 90 patients (76%). Another 6 patients reached CR after 3-4 induction courses for a total CR rate of 81%. If feasible, patients were offered either allogeneic or unpurged autologous bone marrow transplantation. Twenty-four patients underwent allogeneic bone marrow transplantation; 15 in first remission, 8 in second remission, 1 in early relapse. Thirty patients below 56 yr of age underwent autologous bone marrow transplantation in first remission. The overall probability of survival at 4 yr was 34%, and for patients below 40 yr of age 50%. Leukemia-free survival was 35% for the whole cohort of patients; 52% for patients below 40 yr of age. Patients under...Continue Reading

References

Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W R VoglerP L Banks
Apr 1, 1991·European Journal of Haematology·A WahlinH Jonsson
May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Feb 1, 1986·Clinics in Haematology·N C Gorin
Jan 1, 1988·Acta Medica Scandinavica·L BrinchP Stavem
Dec 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T BüchnerG Zeile
Jun 1, 1981·Annals of Internal Medicine·R P GaleJ Zighelboim
Dec 1, 1994·Leukemia & Lymphoma·J LamvikA Waage
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A J MitusJ H Antin

❮ Previous
Next ❯

Citations

Jan 8, 2004·Journal of the National Cancer Institute·Paul C NathanJoseph Beyene
Nov 26, 2008·Clinical Trials : Journal of the Society for Clinical Trials·Brent LoganNancy Geller

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.